ZyVersa Therapeutics, Inc.
ZVSA
$0.7899
-$0.0111-1.39%
| 09/30/2024 | 06/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -10.33% | -11.62% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -17.59% | -2.57% | |||
| Operating Income | 17.59% | 2.57% | |||
| Income Before Tax | 12.81% | 2.57% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 13.11% | 2.23% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 13.11% | 2.23% | |||
| EBIT | 17.59% | 2.57% | |||
| EBITDA | 17.57% | 2.57% | |||
| EPS Basic | 26.61% | 26.97% | |||
| Normalized Basic EPS | 26.35% | 27.23% | |||
| EPS Diluted | 26.61% | 26.97% | |||
| Normalized Diluted EPS | 26.35% | 27.23% | |||
| Average Basic Shares Outstanding | 18.39% | 33.88% | |||
| Average Diluted Shares Outstanding | 18.39% | 33.88% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
